Correlation of type 1 diabetes trends in European countries to the number of bovine insulin and GAD65 contaminated chick embryo cell culture containing vaccines in the schedule, as predicted by the autoimmunity mechanism involving immunization with homologous xenogeneic antigens and EPIT as a potential treatment

Type 1 diabetes (T1D) affects millions and is a growing problem worldwide. The etiology of T1D is considered to be unknown.
Many vaccines are manufactured using bovine milk derived proteins such as bovine casein and casamino acids as growth media to grow bacteria. These vaccines contain trace quantities of all bovine milk proteins.
Similarly, other vaccines are manufactured using animal cells such as chick embryo cell culture, to grow viruses. These vaccines contain trace quantities of chick embryo proteins.
Such non-target protein content in vaccines are not regulated. No safe levels of such proteins in vaccines have been determined. There are no specifications controlling the amount of such proteins in vaccines. A recent example is the case of Pandemrix induced narcolepsy, where Arepanrix and Pandemrix vaccines made by the same vendor, GSK, at two different facilities, contained differing amounts of H1N1 nucleoproteins thus resulting in a big difference in the incidence of vaccine-induced narcolepsy. The safety claims of such vaccines are based on studies that misinterpret the statistics and have therefore come to the wrong conclusion regarding safety.
Animal proteins have molecular mimicry to human proteins. Therefore immune responses generated against animal proteins can result in cross reaction to human proteins. The result is autoimmune disorders such as type 1 diabetes (T1D).
The trends and cyclical variation of type 1 diabetes incidence in European countries was recently described. The cyclical variation can be explained by the interval between vaccine doses. Positive correlation is shown between the number of milk protein and chick embryo cell culture containing vaccines on the schedule and the rate of increase in T1D.